1. Takeichi M. Dynamic contacts: rearranging adherens junctions to drive epithelial remodelling. Nat Rev Mol Cell Biol 2014;15:397–410.
2. Halbleib JM, Nelson WJ. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev 2006;20:3199–3214.
3. Larue L, Ohsugi M, Hirchenhain J, Rolf Kemler. E-cadherin null mutant embryos fail to form a tro- phectoderm epithelium. Proc Natl Acad Sci U S A 1994;91:8263–8267.
4. Nakagawa H, Hikiba Y, Hirata Y, Font-Burgada J, Sakamoto K, Hayakawa Y, Taniguchi K, Umemura A, Kinoshita H, Sakitani K, Nishikawa Y, Hirano K, Ikenoue T, Ijichi H, Debanjan D, Shibata W, Akanuma M, Koike K, Karin M, Maeda S. Loss of liver E-cadherin in- duces sclerosing cholangitis and promotes carcinogen- esis. Proc Natl Acad Sci U S A 2014;111:1090–1095.
5. Nakada S, Tsuneyama K, Kato I, Tabuchi Y, Takasaki I, Furusawa Y, Kawaguchi H, Fujimoto M, Goto H, Hikiami H, Kondo T, Takano Y, Shimada Y. Identification of candidate genes involved in endogenous protection mechanisms against acute pancreatitis in mice. Biochem Biophys Res Commun 2010;391:1342–1347.
6. Lerch MM, Lutz MP, Weidernbach H, Pillasch FM, Gress TM, Leser J, Adler G. Dissociation and reassembly of adherens junctions during experimental acute pancreatitis. Gastroenterology 1997;113:1355–1366.
7. Deng S, Zhu S, Wang B, Li X, Liu Y, Qin Q, Gong Q, Niu Y, Xiang C, Chen J, Jin Y, Deng S, Yin T, Yang M, Wu H, Wang C, Zhao G. Chronic pancreatitis and pancreatic cancer demonstrate active epithelial- mesenchymal transition profile, regulated by miR-217-SIRT1 pathway. Cancer Lett 2014;355:184–191.
8. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994;54:3845–3852.
9. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015;16:e60–e70.
10. Hayakawa Y, Ariyama H, Stancikova J, Sakitani K, Asfaha S, Renz BW, Dubeykovskaya ZA, Shibata W, Wang H, Westphalen CB, Chen X, Takemoto Y, Kim W, Khurana SS, Tailor Y, Nagar K, Tomita H, Hara A, Seplveda AR, Setlik W, Gershon MD, Saha S, Ding L, Shen Z, Fox JG, Friedman RA, Konieczny SF, Worthley DL, Korinek V, Wang TC. Mist1 expressing gastric stem cells maintain the normal and neoplastic gastric epithelium and are supported by a perivascular stem cell niche. Cancer Cell 2015;28:800–814.
11. Kinoshita H, Hayakawa Y, Konishi M, Hara M, Tsuboi M, Hayata Y, Hikiba Y, Ihara S, Nakagawa H, Ikenoue T, Ushiku T, Fukuyama M, Hirata Y, Koike K. Three types of metaplasia models through Kras activation, Pten dele- tion, or Cdh1 deletion in the gastric epithelium. J Pathol 2019;247:35–47.
12. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y, Fukamichi H, Jonkers J, Tanaka H, Eishi Y, Yuasa Y. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse- type gastric cancer. Gut 2012;61:344–353.
13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
14. Chen L, Ma C, Bian Y, Shao C, Wang T, Li J, Chong X, Su L, Lu J. Aberrant expression of STYK1 and E-cad- herin confer a poor prognosis for pancreatic cancer pa- tients. Oncotarget 2017;8:111333–111345.
15. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172:973–981.
16. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57:1731–1734.
17. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CVE, Hruban RH, Lowy AM, Tuveson DA. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437–450.
18. Shibata W, Kinoshita H, Hikiba Y, Sato T, Ishii Y, Sue S, Sugimori M, Suzuki N, Sakitani K, Ijichi H, Mori R, Endo I, Maeda S. Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. Sci Rep 2018;8:6150.
19. Wang M, Han J, Marcar L, Black J, Liu Q, Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, Hong TS, Gurtner K, Krause M, Baumann M, Kang JX, Whetstine JR, Willers H. Radiation resistance in KRAS- mutated lung cancer is enabled by stem-like properties mediated by an osteopontin-EGFR pathway. Cancer Res 2017;77:2018–2028.
20. Cai MH, Xu XG, Yan SL, Sun Z, Ying Y, Wang BK, Tu YX. Depletion of HDAC1, 7 and 8 by histone deacetylase inhi- bition confers elimination of pancreatic cancer stem cells in combination with gemcitabine. Sci Rep 2018;8:1621.
21. Serrill JD, Sander M, Shih HP. Pancreatic exocrine tissue architecture and integrity are maintained by E-cadherin during postnatal development. Sci Rep 2018;8:13451.
22. Tinkle CL, Lechler T, Pasolli HA, Fuchs E. Conditional targeting of E-cadherin in skin: insights into hyper- proliferative and degenerative responses. Proc Natl Acad Sci U S A 2004;101:552–557.
23. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort, Peterse JL, Cardiff RD, Berns A, Jonkers J. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006;10:437–449.
24. Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Mouse models of pancreatic cancer. World J Gastro- enterol 2012;18:1286–1294.
25. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469–483.
26. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17:3112–3126.
27. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor pro- gression? Oncogene 2008;27:6920–6929.
28. Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B, Seruca R, Roviello F, Oliveira C. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 2013; 31:868–875.
29. Stuebs F, Heidemann S, Caliebe A, Mundhenke C, Arnold N. CDH1 mutation screen in a BRCA1/2-negative familial breast-/ovarian cancer cohort. Arch Gynecol Obstet 2018;297:147–152.
30. Busch EL, Hornick JL, Umeton R, Albayrak A, Lindeman NI, MacConail LE, Garcia EP, Ducar M, Rebbeck TR. Somatic mutations in CDH1 and CTNNB1 in primary carcinomas at 13 anatomic sites. Oncotarget 2017;8:85680–85691.
31. Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, Gu H, Ng LL, Palmiter RD, Hawrylycz MJ, Jones AR, Lein ES, Zeng H. A robust and high- throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci 2010; 13:133–140.
32. Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyazaki A. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applica- tions. Nat Biotechnol 2002;20:87–90.
33. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compen- satory proliferation that promotes chemical hep- atocarcinogenesis. Cell 2005;121:977–990.
34. Skrypek N, Goossens S, De Smedt E, Vandamme N, Berx G. Epithelial-to-mesenchymal transition: epigenetic reprogramming driving cellular plasticity. Trends Genet 2017;33:943–959.
35. Shibata H, Komura S, Yamada Y, Sankoda N, Tanaka A, Ukai T, Kabata M, Sakurai S, Kuze B, Woltjen K, Haga H, Ito Y, Kawaguchi Y, Yamamoto T, Yamada Y. In vivo reprogramming drives Kras-induced cancer develop- ment. Nat Commun 2018;9:2081.
36. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2018; 133:704–715.
37. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and meta- static activity in human pancreatic cancer. Cell Stem Cell 2007;1:313–323.
38. Li XP, Zhang XW, Zheng LZ, Guo WJ. Expression of CD44 in pancreatic cancer and its significance. Int J Clin Exp Pathol 2015;8:6724–6731.
39. Wei D, Wang L, Yan Y, Jia Z, Gagea M, Li Z, Zuo X, Kong X, Huang S, Xie K. KLF4 is essential for induction of cellular identity change and acinar-to-ductal reprog- ramming during early pancreatic carcinogenesis. Cancer Cell 2016;29:324–338.
40. He P, Yang JW, Yang VW, Bialkowska AB. Kruppel-like factor 5, increased in pancreatic ductal adenocarcinoma, promotes proliferation, acinar-to-ductal metaplasia, pancreatic intraepithelial neoplasia, and tumor growth in mice. Gastroenterology 2018;154:1494–1508 e13.
41. Orlandini LF, Reis F, da Silveira WA, Tiezzi MG, de Andrade JM, Silva AR, Deaton R, Bosland M, Tizzi DG. Identification of a subtype of poorly differentiated inva- sive ductal carcinoma of the breast based on vimentin and E-cadherin expression. Rev Bras Ginecol Obstet 2018;40:779–786.
42. Zheng X, Carstens JL, Kim J, Matthew Scheible, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R. Epithelial-to- mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Na- ture 2015;527:525–530.
43. Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross- resistance to a wide range of DNA-damaging drugs. Cancer Sci 2008;99:376–384.
44. Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heiecke CD, Friess H, Buchler, Evert M, Lerch MM, Weiss FU. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 2012;61:439–448.
45. Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Abramson RG, Yankeelov TE, Hiebert S, Merchant N, Bhaskara S, Chakravarthy AB. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiother Oncol 2016;119:312–318.
46. Pan FC, Bankaitis ED, Boyer D, Xu X, Van de Casteele M, Magnuson MA, Heimberg H, Wright CVE. Spatiotem- poral patterns of multipotentiality in Ptf1a-expressing cells during pancreas organogenesis and injury- induced facultative restoration. Development 2013; 140:751–764.
47. Kopinke D, Brailsford M, Pan FC, Magnuson MA, Wright XVE, Murtaugh LC. Ongoing Notch signaling maintains phenotypic fidelity in the adult exocrine pancreas. Dev Biol 2012;362:57–64.